Genmab Lands Experienced Partner AbbVie In Broad Bispecific Antibody Collaboration

AbbVie will pay $750m up front plus up to $3.15bn in milestone fees to jointly develop and commercialize three bispecific antibody candidates for cancer and an earlier drug discovery collaboration.

Genmab Office Copenhagen - close up
Genmab hopes to grow into a commercial company • Source: Genmab

Danish antibody developer Genmab AS has landed AbbVie Inc. as a big pharma partner to jointly develop and commercialize three of its next-generation bispecific antibody candidates for cancer, including epcoritamab for B-cell malignancies. The companies announced the broad collaboration on 10 June, under which AbbVie agreed to pay $750m upfront and potential milestone payments of up to $3.15bn.

"Genmab and AbbVie will be equal partners, working together to jointly make all strategy, clinical development and commercialization decisions," Genmab CEO Jan van de

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By 

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By 

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By 

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

More from Business

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By 

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

How Much Does Biopharma Contribute To The US Economy?

 

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.